Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
about
Overexpression of Wnt5a promotes angiogenesis in NSCLC.Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis.Hypoxia induced CCL28 promotes angiogenesis in lung adenocarcinoma by targeting CCR3 on endothelial cellsPD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells.A killer choice for cancer immunotherapy.Immunotherapy and lung cancer: current developments and novel targeted therapies.Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.VEGF as a potential target in lung cancer.Newly developed anti-angiogenic therapy in non-small cell lung cancer.
P2860
Q33791918-8F990980-BA2C-4B55-A68D-E85B0A9AFE3CQ34277777-C88F10D9-A4BB-49C0-93DE-80F993D4635AQ36959390-AD9918B5-9FA5-414B-B494-27CC686FA353Q37222072-6E54D23C-5C76-40A2-B58F-3372E89AF932Q37516448-0E934FE7-4A20-414E-90B8-13AC4A7918AEQ38199717-23E30A6B-A506-4A7D-90C5-25BBA8D7C470Q38208944-24F2E5B2-42F1-4C7B-AF99-4E37AE0186C8Q38286376-692B432E-B5F6-4F3E-9DDC-387E83EDCAA9Q40200213-936A4ACF-D692-4E8D-A9D9-AE890258E66AQ47135054-F49AAED9-182D-4C6C-8D8F-9C339A319B85Q47918409-EA4E6B83-5C65-410A-8645-46B809E93A8DQ52668159-06ED0FC3-5485-4E01-A768-F5417982E42D
P2860
Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Bevacizumab improves the antit ...... small cell lung cancer models.
@en
Bevacizumab improves the antit ...... small cell lung cancer models.
@nl
type
label
Bevacizumab improves the antit ...... small cell lung cancer models.
@en
Bevacizumab improves the antit ...... small cell lung cancer models.
@nl
prefLabel
Bevacizumab improves the antit ...... small cell lung cancer models.
@en
Bevacizumab improves the antit ...... small cell lung cancer models.
@nl
P2093
P2860
P1433
P1476
Bevacizumab improves the antit ...... small cell lung cancer models.
@en
P2093
Guichun Huang
Leilei Tao
Longbang Chen
Shujing Shi
P2860
P2888
P356
10.1007/S12032-013-0777-3
P577
2013-11-24T00:00:00Z